BICELTIS 440MG

Biceltis 440mg Injection contains Trastuzumab as its active ingredient, which is indicated for the treatment of HER2-positive breast cancer. In patients with HER2 positivity, the breast cancer cells predominantly feature HER2 proteins that facilitate the rapid growth of cancer tumors by acting as signals to the malignant cells.

Additionally, this medication is utilized for the treatment of metastatic gastric cancer characterized by elevated levels of HER2 proteins.

HER2-positive breast cancer is known for its aggressive nature. The targeted therapy for HER2-positive breast cancer functions by specifically targeting the proteins that contribute to the growth, development, and dissemination of cancer. It is advised to use effective birth control during the treatment and for at least seven months following the last dose.

Biceltis 440mg Injection is not recommended for individuals under 18 years of age or for those with severe respiratory issues or who require oxygen therapy. It is essential to inform your healthcare provider if you have any heart conditions, experience breathlessness, or have previously undergone any other cancer treatments.

Ensure that you disclose all medications, including supplements and herbal products, you are currently taking to your physician before commencing treatment with this medication.